• By ICR Secretariat
  • Posted Tuesday, February 21, 2017

EMA reviews Actelion PAH drug after patient deaths

http://www.biopharmadive.com/news/ema-reviews-actelion-pah-drug-after-patient-deaths/436226/

The European Medicines Agency has launched a safety review of Actelion Pharma's pulmonary arterial hypertension medicine Uptravi (selexipag) to investigate the deaths of 5 patients taking the drug in France.

 

Image credit: Actelion